The patient, a 78-year-old female, began showing signs of a negative reaction within 20 hours. 

In a new statement, the CDC, American Heart Association and several other healthcare organizations highlighted the continued importance of vaccination. 

The study's authors called for additional research in this area, noting that it may be beneficial to screen all heart failure patients for cancer. 

The approval includes patients as young as three months old. 

The study's authors examined data from more than 21,000 participants. 

This new measurement, researchers explained, can help clinicians target high-risk patients with more aggressive treatments. 

The SGLT2 inhibitor was approved for this new indication based on results from the EMPEROR-Reduced trial.

The U.S. military’s universal healthcare system has proved to be a big benefit for one group of patients, according to a new study.